India:
Biosimilars – IP Strategy And Commercialization Aspects
To print this article, all you need is to be registered or login on Mondaq.com.
Biosimilars are highly similar to the reference product
notwithstanding minor differences in clinically inactive
components. There are no clinically meaningful differences between
the biological product and the reference product in terms of the
safety, purity, and potency of the product. Advances in current
state-of-the art analytical methods enhance the likelihood that a
product will be highly similar to another product by better
targeting the original product’s physicochemical and
functional properties.
Biosimilars – IP Strategy and Commercialization Aspects by
Harshada Wadkar
https://www.lexology.com/library/detail.aspx?g=46c4f349-2d60-4044-abf9-26c8118d93af
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from India
Legal Implications Of AI-Created Works In India
Khurana and Khurana
AI has become a buzzword in our lives, considering its role and impact. It has its pros and cons that is to be governed by law and order. This Blog delves into these issues, exploring AI's potential and future, especially in the context of Indian laws.
What Is Fair Use Of Copyright Doctrine?
Photon legal
Have you ever used a copyrighted work without permission, and wondered whether it was legal or not? You might have heard of the term "fair use," but what exactly does it mean?
An Overview Of Evergreening Patents
Photon legal
Do you know that there's a way to evergreen your patents? Evergreen, as the name suggests, is something that will last for a lifetime. Therefore, Evergreening of patents is a process...